were compared for WNT10B using IHC Real-Time RT PCR: RNA isolated using RNeasy kit, reverse transcribed with iScript and quantified using BioRad SoSoAdvanced SYBR kit. Stable knockdown: WNT10B and Control lentiviral constructs were used to create stable WNT10B knockdown in PC3 cells Cell Proliferation Assay: MTT assay assessed proliferation Side Population Analysis: Hoechst exclusion assay was used to assess stem-like cell side population Xenograft development: Primary xenografts were developed subcutaneously in nude mice and harvested at 30 days. Serial transplantation was performed subcutaneously and under the renal capsule with harvest at 9 weeks.
INTRODUCTION AND OBJECTIVES:
The cancer driver gene CCCTC-binding factor (CTCF) coordinates epigenetic signaling and interacts with cofactors such as BORIS and CHD8 that affect its function. CTCF is deleted in roughly 30% of prostate and other cancers, but loss of function may occur more frequently. Our objective is to generate a CTCF gene signature that reports loss of CTCF function regardless of how that function may be inactivated, and to determine whether the signature could inform disease aggression.
METHODS: CTCF was knocked-down by multiple shRNAs in cell lines and transcriptomes examined by RNA-seq. A shared gene expression signature was generated and used to query primary prostate cancer data in the TCGA and MSK databases. Clinicopathological parameters and gene expression values were compared between patients with this signature and those without. Ontological analysis on genes that are differentially expressed between the 2 tumor groups was performed and identified pathways were tested to determine if they were necessary for cell proliferation and survival in the absence of CTCF.
RESULTS: Transcriptome analysis following CTCF knockdown revealed a 74 gene signature comprised of 45 up-regulated and 29 down-regulated genes. Tumors with upregulated signature genes had higher Gleason scores (8 vs 7.5; p<0.01). Expression of known CTCF cofactor genes such as CHD8, RAD21, SMC1A, SMC3, STAG1 and STAG2 were also decreased in patients displaying this signature. STRING analysis revealed that genes in this signature are involved in L-glutamine transmembrane transport, a well characterized coordinator of tumor growth and proliferation. Subsequently, we demonstrate that reduced L-glutamine levels decreases proliferation of CTCF deficient prostate cancer cell lines but not controls.
CONCLUSIONS: We have generated a unique 'broken CTCF' signature in patients and found this to be associated with worse tumor outcomes than in patients without this signature. These adverse outcomes could be due in part to alterations in amino acid transmembrane transport as CTCF deficient cells are sensitive to reductions in Lglutamine levels. This suggests unique metabolic approaches may be useful in the control of CTCF altered tumors.
Source of Funding: DOD PC140574
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OVERCOMING PROSTATE CANCER THERAPEUTIC RESISTANCE BY MODULATING MITOCHONDRIA-MEDIATED CELL METABOLISM AND DEATH SIGNALING Ji Lyu*, Gina Chia-Yi Chu, Yi Zhang, Sungyong You, Stefan Mrdenovic, Los Angeles, CA; Chengfei Liu, Allen C. Gao, Sacramento, CA; Haiyen E. Zhau, Leland W.K Chung, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Castration-resistant prostate cancer (CRPC) invariably develops resistance to androgen antagonists enzalutamide and abiraterone and taxane-based docetaxel. We tested a novel heptamethine carbocyanine dye conjugated to cholesterol-lowering simvastatin, DZ-SIM, which localizes only in PCa cells and xenografts, for its anti-tumor-targeting and mechanisms of action in enzalutamide (MDVR), abiraterone (AbiR) and docetaxel (TaxR) resistant PCa cells and xenografts.
METHODS: We used parental C4-2B, MDVR, AbiR, TaxR C4-2B, and 22RV1 cells for cell proliferation, apoptosis, and mechanistic studies. Cell proliferation was assessed by crystal violet, DZ-SIM distribution by Mito-or Lyso-tracker, and PCa metabolism and oxygen consumption by Seahorse XF24 extracellular flux analyzer for extracellular acidification rate (ECAR), oxygen consumption rate (OCR), and fatty acid oxidation (FAO). Flow cytometry was used to assess mitochondria membrane integrity and apoptosis. RNA-seq data underwent computational analyses for shared common genes. Results were validated by qRT-PCR and in vitro studies.
RESULTS: DZ-SIM, but not DZ or SIM alone, inhibited PCa cell growth rapidly (<16 hrs) and efficiently (100%) in a time and dosedependent manner in vitro. DZ-SIM accumulates in mitochondrial and lysosomal subcellular organelles to decrease cell and mitochondrial membrane cholesterol levels. Decreased mitochondrial membrane potential, increased DNA fragmentation and PCa cell death were documented by flow cytometry. DZ-SIM depressed mitochondrial OCR, and FAO in MDVR, AbiR, and TaxR C4-2B cells but stimulated cytosolic glycolysis as assessed by ECAR. RNA Seq analysis of parental and resistant C4-2B cells revealed 72 shared common genes, over 10% of which were mitochondrial related. DZ-SIM specifically downregulated CAMK2N1, HMGCS2, NR2F1 and CDH3 target genes as confirmed by qRT-PCR and by in vitro studies, effectively inhibiting tumor growth in both intratibial and subcutaneous TaxR PCa models.
CONCLUSIONS: RNA Seq analysis of parental and MDVR, AbiR, and TaxR C4-2B cells revealed shared common genes. DZ-SIM inhibited the growth of all resistant C4-2B cells by targeting mitochondria-mediated and cellular metabolic machinery, and can be developed as a sensitizer for hormone and chemotherapy resistant PCa.
